金吾财讯 | 国泰海通发研报指，在英国首相访华期间，阿斯利康宣布计划在中国投资150亿美元。近日，英国首相斯塔默开启为期4天的访华行程，随同斯塔默访问的有超50家企业高管和机构代表。其中，阿斯利康全球首席执行官苏博科、葛兰素史克董事会主席司明麒作为英国医药产业的代表随团访华。这项投资用于扩大药品制造和研发。这项投资将充分利用中国卓越的科学实力、先进的制造能力以及中英医疗健康生态系统合作优势，为中国及全球患者提供尖端治疗方案。投资具体用途：1）位于北京和上海的全球战略研发中心；2）扩建位于无锡、泰州、青岛和北京的现有生产基地，并同时还将设立新的生产基地；3）扩展在中国的高技能员工队伍至超过20,000人。该机构认为，本次投资再次证明在中国工程师红利及生物医药能力的持续验证下，MNC对于中国本土研发能力及中国市场的兴趣和认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.